News | February 17, 2022
Asahi Kasei to build new filter assembly plant in Japan
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Funding to grow the insurance and digital therapeutics vertical in India
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
The entire integration and transition of the brands is expected to be completed by March 2022
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Key takeaways of Q3FY22 quarter & conference call highlights
The recommendation has been sent to the DCGI for approval
Subscribe To Our Newsletter & Stay Updated
